Gilead Sciences Inc (GILD) has a mixed performance in the market with its stock value experiencing ups and downs, yet, the company increased its dividend to $0.77. Gilead announced mixed Q1 2024 earnings, topping revenue estimates but missing analyst EPS estimates amidst growth in HIV and Oncology. The company also recently completed the acquisition of CymaBay and partnered with Xilio on a Tumor-Activated IL-12 Program. However, disappointing results from Trodelvy's lung cancer trial caused a significant drop in stock price. Despite several setbacks, GILD still shows potential as an attractive longer-term investment.
Gilead Sciences GILD News Analytics from Tue, 07 Nov 2023 08:00:00 GMT to Thu, 09 May 2024 05:07:00 GMT - Rating -3 - Innovation -2 - Information 8 - Rumor -4
